Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
World Vaccine Conferen...World Vaccine Conference
Not Confirmed
Not Confirmed
22-24 April, 2025
Not Confirmed
Not Confirmed
22-25 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
World Vaccine Conferen...World Vaccine Conference
Industry Trade Show
Not Confirmed
22-24 April, 2025
Industry Trade Show
Not Confirmed
22-25 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
24 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/jj-and-eli-lilly-concealed-breast-cancer-risks-in-blockbuster-antipsychotics-for-decades-wisner-baum-lawsuit-alleges-302436429.html
23 Apr 2025
// REUTERS
https://www.reuters.com/sustainability/boards-policy-regulation/lilly-sues-four-compounders-over-copies-weight-loss-drugs-2025-04-23/
19 Apr 2025
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-pill-leads-79-weight-loss-40-weeks-trial-2025-04-17/
18 Apr 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/eli-lilly-overtaking-novo-nordisk-diabetesobesity-market-analysts
18 Apr 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/lillys-oral-glp-1-drug-delivers-ozempic-efficacy-phase-3-diabetes-trial
17 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/lilly-confirms-date-and-conference-call-for-first-quarter-2025-financial-results-announcement-302430685.html
Details:
The collaboration combines BigHat's AL/ML-powered Milliner platform with Lilly's expertise in drug discovery to develop high-quality next-generation antibodies.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Antibody
Recipient: BigHat Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 17, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : BigHat Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
BigHat Biosciences and Lilly Collaborate to Advance AI-Driven Antibody Therapeutics
Details : The collaboration combines BigHat's AL/ML-powered Milliner platform with Lilly's expertise in drug discovery to develop high-quality next-generation antibodies.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
April 17, 2025
Details:
LY3502970 (orforglipron hemicalcium hydrate) is a once-daily oral nonpeptide GLP-1 receptor agonist. It is being evaluated in phase 3 clinical trials for the treatment of adults with Type 2 Diabetes.
Lead Product(s): Orforglipron Calcium Hydrate
Therapeutic Area: Endocrinology Brand Name: LY3502970
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 17, 2025
Lead Product(s) : Orforglipron Calcium Hydrate
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lilly’s Oral GLP-1 Orforglipron Shows Success in Phase 3 with Comparable Safety
Details : LY3502970 (orforglipron hemicalcium hydrate) is a once-daily oral nonpeptide GLP-1 receptor agonist. It is being evaluated in phase 3 clinical trials for the treatment of adults with Type 2 Diabetes.
Product Name : LY3502970
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 17, 2025
Details:
Mounjaro (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently it is indicated for the treatment of type 2 diabetes mellitus and obesity.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Brand Name: Mounjaro
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 20, 2025
Lead Product(s) : Tirzepatide
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eli Lilly Launches Weight-Loss Drug Mounjaro in India After Drug Regulator Approval
Details : Mounjaro (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently it is indicated for the treatment of type 2 diabetes mellitus and obesity.
Product Name : Mounjaro
Product Type : Peptide
Upfront Cash : Inapplicable
March 20, 2025
Details:
Olumiant (baricitinib) is an oral JAK1/JAK2 inhibitor, small molecule drug candidate, which is being evaluated for the treatment of severe alopecia areata.
Lead Product(s): Baricitinib
Therapeutic Area: Dermatology Brand Name: Olumiant
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 08, 2025
Lead Product(s) : Baricitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lilly’s Baricitinib Shows High Hair Regrowth Rates in Adolescents
Details : Olumiant (baricitinib) is an oral JAK1/JAK2 inhibitor, small molecule drug candidate, which is being evaluated for the treatment of severe alopecia areata.
Product Name : Olumiant
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 08, 2025
Details:
Jaypirca (pirtobrutinib) is an oral small molecule, BTK inhibitor which being developed for the treatment of adults with R/R chronic lymphocytic leukemia.
Lead Product(s): Pirtobrutinib
Therapeutic Area: Oncology Brand Name: Jaypirca
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 28, 2025
Lead Product(s) : Pirtobrutinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CHMP Recommends Lilly’s Jaypirca for Relapsed Chronic Lymphocytic Leukemia
Details : Jaypirca (pirtobrutinib) is an oral small molecule, BTK inhibitor which being developed for the treatment of adults with R/R chronic lymphocytic leukemia.
Product Name : Jaypirca
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2025
Details:
LY3540378 (volenrelaxin) is a RXFP1 agonist, fusion protein drug candidate, which was being evaluated for the treatment of chronic kidney disease in adults.
Lead Product(s): Volenrelaxin
Therapeutic Area: Nephrology Brand Name: LY3540378
Study Phase: Phase IIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 29, 2025
Lead Product(s) : Volenrelaxin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lilly Ends Relaxin Study in CKD for Lack of Clinical Benefit
Details : LY3540378 (volenrelaxin) is a RXFP1 agonist, fusion protein drug candidate, which was being evaluated for the treatment of chronic kidney disease in adults.
Product Name : LY3540378
Product Type : Protein
Upfront Cash : Inapplicable
January 29, 2025
Details:
LY3437943 (retatrutide) is a GCGR/GLP-1R agonist synthetic peptide candidate, which is currently being evaluated for the treatment of Atherosclerotic Cardiovascular Disease in adult.
Lead Product(s): Retatrutide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: LY3437943
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 19, 2025
Lead Product(s) : Retatrutide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CDSCO Panel Approves Eli Lilly's Protocol Amendment Proposal for Retatrutide Study
Details : LY3437943 (retatrutide) is a GCGR/GLP-1R agonist synthetic peptide candidate, which is currently being evaluated for the treatment of Atherosclerotic Cardiovascular Disease in adult.
Product Name : LY3437943
Product Type : Peptide
Upfront Cash : Inapplicable
January 19, 2025
Details:
Omvoh (mirikizumab) is the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis & crohn's disease in adults.
Lead Product(s): Mirikizumab
Therapeutic Area: Gastroenterology Brand Name: Omvoh
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 15, 2025
Lead Product(s) : Mirikizumab
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lilly’s Omvoh® Gets FDA Approval for Crohn’s Disease Expansion
Details : Omvoh (mirikizumab) is the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis & crohn's disease in adults.
Product Name : Omvoh
Product Type : Antibody
Upfront Cash : Inapplicable
January 15, 2025
Details:
Through the acquisition, Lupin will enhance its portfolio and gain the right to commercialize Humulin N (human insulin) in India. It is indicated for the treatment of diabetes mellitus.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Brand Name: Humulin N
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Lupin Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 30, 2024
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
Lupin Acquires Huminsulin from Lilly, Enhance Diabetes Portfolio
Details : Through the acquisition, Lupin will enhance its portfolio and gain the right to commercialize Humulin N (human insulin) in India. It is indicated for the treatment of diabetes mellitus.
Product Name : Humulin N
Product Type : Peptide
Upfront Cash : Undisclosed
December 30, 2024
Details:
Zepbound (tirzepatide) injection is a first obstructive sleep apnea in adults with obesity treatment of its kind that activates both GIP/GLP-1 hormone receptors.
Lead Product(s): Tirzepatide
Therapeutic Area: Sleep Brand Name: Zepbound
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2024
Lead Product(s) : Tirzepatide
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Zepbound® (Tirzepatide) for Obstructive Sleep Apnea in Adults with Obesity
Details : Zepbound (tirzepatide) injection is a first obstructive sleep apnea in adults with obesity treatment of its kind that activates both GIP/GLP-1 hormone receptors.
Product Name : Zepbound
Product Type : Peptide
Upfront Cash : Inapplicable
December 20, 2024
Regulatory Info : Originator
Registration Country : South Africa
50% Insulin Lispro Protamine Suspension (Npl)
Dosage Form : PED
Brand Name : Humalog Mix50
Dosage Strength : 100IU/ml
Packaging : 3X5IU/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
50% Insulin Lispro Protamine Suspension (Npl)
Dosage Form : CAT
Brand Name : Humalog Mix50
Dosage Strength : 100iu/ml
Packaging : 3X5iu/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
75% Insulin Lispro Protamine Suspension (Npl)
Dosage Form : CAT
Brand Name : Humalog Mix25
Dosage Strength : 100iu/ml
Packaging : 3X5iu/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
75% Insulin Lispro Protamine Suspension (Npl)
Dosage Form : PED
Brand Name : Humalog Mix25
Dosage Strength : 100iu/ml
Packaging : 3X5iu/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
75% Insulin Lispro Protamine Suspension (Npl)
Dosage Form : PED
Brand Name : Humalog Mix 25
Dosage Strength : 100iu/ml
Packaging : 3X5iu/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
75% Insulin Lispro Protamine Suspension (Npl)
Dosage Form : SUS
Brand Name : Humalog Mix25
Dosage Strength : 100iu/ml
Packaging : 10X1iu/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Dosage Form : INJ
Brand Name : Reopro
Dosage Strength : 10mg/5ml
Packaging : 5X1mg/5ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Prescription
Registration Country : Canada
Dosage Form : TABLET
Brand Name : VERZENIO
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number : 2487101
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : RX
Registration Country : USA
Dosage Form : TABLET;ORAL
Brand Name : VERZENIO
Dosage Strength : 150MG
Packaging :
Approval Date : 2017-09-28
Application Number : 208716
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : USA
Dosage Form : TABLET;ORAL
Brand Name : VERZENIO
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number : 208855
Regulatory Info :
Registration Country : USA
RLD : Yes
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : VERZENIO
Dosage Strength : 50MG
Approval Date : 2017-09-28
Application Number : 208716
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : VERZENIO
Dosage Strength : 100MG
Approval Date : 2017-09-28
Application Number : 208716
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : VERZENIO
Dosage Strength : 150MG
Approval Date : 2017-09-28
Application Number : 208716
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : VERZENIO
Dosage Strength : 200MG
Approval Date : 2017-09-28
Application Number : 208716
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD :
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : VERZENIO
Dosage Strength : 50MG
Approval Date :
Application Number : 208855
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : VERZENIO
Dosage Strength : 100MG
Approval Date :
Application Number : 208855
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : VERZENIO
Dosage Strength : 150MG
Approval Date :
Application Number : 208855
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : VERZENIO
Dosage Strength : 200MG
Approval Date :
Application Number : 208855
RX/OTC/DISCN :
RLD :
TE Code :
RLD : No
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : DYMELOR
Dosage Strength : 500MG
Approval Date : 1982-01-01
Application Number : 13378
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : DYMELOR
Dosage Strength : 250MG
Approval Date : 1982-01-01
Application Number : 13378
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Film-Coated Tablets
Dosage Strength : 100mg
Packaging :
Brand Name : Verzenios
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Film-Coated Tablets
Dosage Strength : 100mg
Packaging :
Brand Name : Verzenios
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Filmtabl
Dosage Strength : 150mg
Packaging :
Brand Name : Verzenios
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Filmtabl
Dosage Strength : 150mg
Packaging :
Brand Name : Verzenios
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Film-Coated Tablets
Dosage Strength : 50mg
Packaging :
Brand Name : Verzenios
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Film-Coated Tablets
Dosage Strength : 50mg
Packaging :
Brand Name : Verzenios
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Norway
Dosage Form : Capsule, hard
Dosage Strength : 10 mg
Packaging : Blister
Brand Name : Strattera
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Dosage Form : Capsule, hard
Dosage Strength : 10 mg
Packaging : Blister
Brand Name : Strattera
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Dosage Form : Capsule, hard
Dosage Strength : 100 mg
Packaging : Blister
Brand Name : Strattera
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Dosage Form : Capsule, hard
Dosage Strength : 18 mg
Packaging : Blister
Brand Name : Strattera
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Excipients
Inspections and registrations
District Decision : Voluntary Action Indicated
Inspection End Date : 2017-07-21
City : Carolina
State : PR
Country/Area : US
Zip : 00987-2705
District : SJN
Center : CDER
Project Area : Drug Quality Assurance
District Decision : Voluntary Action Indicated
Inspection End Date : 2017-07-21
District Decision : No Action Indicated
Inspection End Date : 2017-05-25
City : Indianapolis
State : IN
Country/Area : US
Zip : 46225-1782
District : DET
Center : CDER
Project Area : Drug Quality Assurance
District Decision : No Action Indicated
Inspection End Date : 2017-05-25
ABOUT THIS PAGE
Eli Lilly is a supplier offers 70 products (APIs, Excipients or Intermediates).
Find a price of Azaperone bulk with CEP offered by Eli Lilly
Find a price of Caninsulin bulk offered by Eli Lilly
Find a price of Enilconazole bulk with CEP offered by Eli Lilly
Find a price of Gemcitabine bulk with CEP offered by Eli Lilly
Find a price of Insulin (Human) Recombinant bulk with JDMF offered by Eli Lilly
Find a price of Insulin Lispro bulk with JDMF offered by Eli Lilly
Find a price of Olanzapine bulk with JDMF offered by Eli Lilly
Find a price of Vincristine Sulfate bulk with CEP offered by Eli Lilly
Find a price of Acetohexamide bulk offered by Eli Lilly
Find a price of Almitrine bulk offered by Eli Lilly
Find a price of Aspirin bulk offered by Eli Lilly
Find a price of Capreomycin bulk offered by Eli Lilly
Find a price of Cefaclor bulk offered by Eli Lilly
Find a price of Cefalotin sodium Sterile bulk offered by Eli Lilly
Find a price of Cefamandole Nafate bulk offered by Eli Lilly
Find a price of Cefamandole Sodium Salt bulk offered by Eli Lilly
Find a price of Cefuroxime Sodium bulk offered by Eli Lilly
Find a price of Cephalexin bulk offered by Eli Lilly
Find a price of Cephalexin Hydrochloride bulk offered by Eli Lilly
Find a price of Cephalexin Monohydrate bulk offered by Eli Lilly
Find a price of Chlormadinone Acetate bulk offered by Eli Lilly
Find a price of Chymotrypsin bulk offered by Eli Lilly
Find a price of Cinoxacin bulk offered by Eli Lilly
Find a price of Closantel Sodium bulk offered by Eli Lilly
Find a price of Cycloserine bulk offered by Eli Lilly
Find a price of Dantrolene bulk offered by Eli Lilly
Find a price of Diclazuril bulk offered by Eli Lilly
Find a price of Diethylstilbestrol bulk offered by Eli Lilly
Find a price of Erythromycin bulk offered by Eli Lilly
Find a price of Erythromycin Estolate bulk offered by Eli Lilly
Find a price of Fenoprofen Calcium bulk offered by Eli Lilly
Find a price of Fluoxetine Hydrochloride bulk offered by Eli Lilly
Find a price of H-Arg-Pro-Pna bulk offered by Eli Lilly
Find a price of Methadone Hydrochloride bulk offered by Eli Lilly
Find a price of Nitroglycerin bulk offered by Eli Lilly
Find a price of Nizatidine bulk offered by Eli Lilly
Find a price of Paracetamol bulk offered by Eli Lilly
Find a price of Penicillin G Procaine bulk offered by Eli Lilly
Find a price of Penicillin V Potassium bulk offered by Eli Lilly
Find a price of Sodium Thiosulfate bulk offered by Eli Lilly
Find a price of Tobramycin bulk offered by Eli Lilly
Find a price of Tobramycin Sulfate bulk offered by Eli Lilly
Find a price of Trypsin bulk offered by Eli Lilly
Find a price of Tylosin bulk offered by Eli Lilly
Find a price of Vancomycin Hydrochloride bulk offered by Eli Lilly
Find a price of TOPICAL ANESTHETIC COMPOUND C-10 bulk offered by Eli Lilly
Find a price of RS-1280 RESIDUALS IN LAYING CHICKENS (VET) bulk offered by Eli Lilly
Find a price of ROTOWEIGH (TM) CAPSULE WEIGHING MACHINE AT USED IN THE INDIANAPOLIS PL bulk offered by Eli Lilly
Find a price of CHLORDIETHYLNOL (DIETHYL CHLORO ETHYNYL CARBINOL) bulk offered by Eli Lilly
Find a price of IMIDAZOLIUM BROMIDE DERIVATIVE bulk offered by Eli Lilly
Find a price of RECOMBINANT PORCINE CARBOXYPEPTIDASE B (RCPB) bulk offered by Eli Lilly
Find a price of MYRISTYL - 3 - HYDROXYBUTYLAMINE HCL - COMPOUND 06537 bulk offered by Eli Lilly
Find a price of MDX-068 (HUMANIZED ANTI-B-AMYLOID MONOCLONAL ANTIBODY) bulk offered by Eli Lilly
Find a price of AMPOULES SODIUM THIOCYANATE, INJECTION COMPOUND #23206 bulk offered by Eli Lilly
Find a price of VORTEL TABLETS bulk offered by Eli Lilly
Find a price of 1 - CYCLOPPENTYL - 2 - AMINO PROPANE bulk offered by Eli Lilly
Find a price of Abemaciclib bulk offered by Eli Lilly
Find a price of Atomoxetin Hydrochloride bulk offered by Eli Lilly
Find a price of Baricitinib bulk offered by Eli Lilly
Find a price of Imlunestrant bulk offered by Eli Lilly
Find a price of Lasmiditan bulk offered by Eli Lilly
Find a price of Olanzapine Pamoate bulk offered by Eli Lilly
Find a price of Olanzapine Tartrate bulk offered by Eli Lilly
Find a price of Pemetrexed Disodium bulk offered by Eli Lilly
Find a price of Pirtobrutinib bulk offered by Eli Lilly
Find a price of Raloxifene Hydrochloride bulk offered by Eli Lilly
Find a price of Selpercatinib bulk offered by Eli Lilly
Find a price of Tadalafil bulk offered by Eli Lilly
Find a price of Tirzepatide bulk offered by Eli Lilly
Find a price of Abemasiclip bulk offered by Eli Lilly